Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation. Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.

Jul 11, 2024 · Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain. Patients also reported less fatigue, a common symptom of MS. “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a ...

Apr 5, 2021 · According to the JAMA study, veterans exposed to Agent Orange are twice as likely to be diagnosed with dementia, compared with veterans who were not exposed.Those who were exposed also developed dementia an average of 1.25 years earlier. The study took into account other competing issues, such as death risk, variables associated with demographics, and both psychiatric and medical comorbidities.

Sep 18, 2017 · The team used the data to create a global model of molecular links to the parasite-infected human brain. They used systems biology to determine the mechanisms through which a T. gondii infection can cause disease.Systems biology involves using computers to create mathematical models of complex biological systems.

May 2, 2024 · The test, developed by Roche in collaboration with Eli Lilly, is intended to support a more accurate Alzheimer’s diagnosis in adults, ages 60 and older, when used with other clinical assessments.. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening or irreversibly debilitating disease.

Nov 22, 2022 · Ongoing INTERCEPT-AD trial still recruiting at multiple sites in US. An ongoing Phase 1 clinical study (NCT04931459), called INTERCEPT-AD, is currently testing how safe and well-tolerated ACU193 is versus a placebo in up to 62 people, age 55–90, with mild cognitive impairment or mild dementia due to Alzheimer’s.. The trial is also testing the antibody’s pharmacokinetics (its movement ...

Recent Posts. The extra tasks when caregiving in a cold climate January 27, 2025; Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation January 3, 2025; The holidays can be challenging for an Alzheimer’s caregiver December 9, 2024; Muna, GSK partner to develop targets for Alzheimer’s treatments December 6, 2024; Modified Kisunla dosing shown to lower risk of ARIA-E in Alzheimer ...

Dec 6, 2017 · PXT864 is an investigational oral combination, using lower doses of repurposed medications, being developed by Pharnext to possibly treat neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).. How PXT864 works. PXT864 is a so-called a pleodrug, meaning that it results from the synergistic combination of medications already ...

Mar 17, 2020 · That result was described in the study “ Impairment of Glycolysis-Derived L-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer’s Disease, ” published in the journal Cell Metabolism. The brain uses large amounts of energy produced from the breakdown, or metabolism, of a type of sugar called glucose.Previous studies have shown that in the early phases of ...

Jul 12, 2019 · The research, “ Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification,” was published in the Journal of Alzheimer’s Disease. Despite their increasing availability, memory assessment tools still have limited accuracy and reliability. MemTrax, which analyzes the ability to recognize images, is presented as a quick and simple way to ...